SCHEMBL6760162

SCHEMBL6760162

Cc1ncc(-c2cc(N)cc(Cl)c2)n1C

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.45
TP53 P04637 2/20 0.45
MAPK1 P28482 2/20 0.45
MAPT P10636 2/20 0.40
DYRK1A Q13627 3/20 0.39
GSK3B P49841 2/20 0.39
CYP3A4 P08684 2/20 0.38
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
MAP4K4 O95819 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
TTK P33981 3/20 0.36
KAT5 Q92993 3/20 0.35
MAP4K1 Q92918 1/20 0.34
CYP17A1 P05093 1/20 0.33
WNT1 P04628 1/20 0.33
KAT7 O95251 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6756618 0.81 ATP1A1 (0.40) USP2TP53MAPK1MAPTDYRK1A
SCHEMBL6754289 0.78 MAPT (0.48) USP2TP53MAPTDYRK1AGSK3B
SCHEMBL3311968 0.77 ATP1A1 (0.43) USP2TP53MAPK1MAPTDYRK1A
SCHEMBL4756995 0.76 DYRK1A (0.47) MAPTDYRK1AGSK3BMAP4K4SMN1; SMN2
SCHEMBL6754326 0.75 MAP4K4 (0.49) USP2MAPTDYRK1ACYP3A4PRMT5
SCHEMBL6755660 0.75 DYRK1A (0.38) MAPK1MAPTDYRK1AGSK3BKAT5
SCHEMBL4756960 0.75 DYRK1A (0.48) MAPK1DYRK1AGSK3BMAP4K4KAT5
SCHEMBL14077000 0.74 USP2 (0.66) USP2TP53MAPK1MAPTDYRK1A
SCHEMBL12492258 0.74 TP53 (0.51) USP2TP53MAPK1MAPTDYRK1A
SCHEMBL12491967 0.73 MAPT (0.49) USP2TP53MAPK1MAPTDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040087798-A1 Novel amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 US disclosed
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
EP-1264820-A1 NOVEL AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 USP2 3081/4885TP53 4553/4885MAPK1 2263/4885
US-20040087798-A1 Novel amide compounds H1-2, H1-0, H1-3 USP2 4276/4885TP53 2814/4885MAPK1 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.